Galderma announced topline results from two phase IIIb trials investigating RelabotulinumtoxinA for the treatment of glabellar lines (GL – frown lines) and lateral canthal lines (LCL – crow’s… read more.
Pregnant individuals with inflammatory bowel disease (IBD) have higher levels of pro-inflammatory immune molecules, known as cytokines, in their vaginal mucosa than their healthy counterparts, according to a new… read more.
A new study has found that for people with moderate hearing loss, being prescribed hearing aids had little impact on cognitive test scores. The study was published on… read more.
Insomnia is frequently underestimated by both the general public and healthcare professionals, often viewed as being part of the “natural order of things” or a transient response to… read more.
Milestone Pharmaceuticals Inc. announced the acceptance of a Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) seeking the approval of etripamil nasal spray, developed to be the… read more.
Doctors encounter death and dying significantly more than most people. It’s the price of saving lives and helping people. Medical students in the U.S., however, receive little or… read more.
Adolescents with Human Immunodeficiency Virus (HIV) in Botswana, South Africa, Thailand, Uganda and the United States who received the injectable intramuscular antiviral medications cabotegravir and rilpivirine for nearly… read more.
Shionogi & Co. Ltd. announced that its group company, Shionogi China Co., Ltd, has received approval from the National Medical Products Administration (NMPA) of China for cefiderocol for… read more.
A new Stanford-led analysis of corporate carbon disclosures finds companies undercount emissions from their supply chains by billions of tons. The shortfall arises from use of a popular… read more.
Despite years of clinical guidelines warning against the practice, one in four Medicare beneficiaries with dementia is prescribed brain-altering medications linked to falls, confusion, and hospitalization, according to… read more.
The European Commission has approved Teizeild (teplizumab) to delay the onset of stage 3 type 1 diabetes (T1D) in adult and pediatric patients eight years of age and… read more.
TV depictions of out-of-hospital cardiac arrest may mislead viewers about who is most likely to need cardiopulmonary resuscitation (CPR) and where it’s needed, according to new research published today in the American… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
